drugset / Trial / NCT03661892

Pilot, Syndros, Decreasing Use of Opioids in Breast Cancer Subjects With Bone Mets

NCT03661892

Phase 0 Completed 14 enrolled University of Arizona
NaSingle-groupOpen-labelTreatment

Summary

In patients with cancer induced bone pain, addition of Syndros will improve pain relief and decrease opioid requirement.

Timeline

Start
2018-12-19
Primary completion
2020-10-30
Completion
2021-04-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Dronabinol Other / unclassified 8.4 mg Oral